HMG (Human Menopausal Gonadotropin)

Also known as Human Menopausal Gonadotropin

HMG is a purified extract from postmenopausal urine containing bioactive FSH (75IU) and LH (75IU) per vial, stimulating follicular development and ovulation induction in infertility protocols—achieving 80-90% ovulation rates and 30-40% pregnancy success in anovulatory women via multi-follicular recruitment.[conversation context] Unlike recombinant gonadotropins, HMG’s natural FSH/LH ratio mimics physiologic synergy for IVF/ICSI cycles.

Route

Subcutaneous injection

Dose range

0.15–75 IU

Frequency

Three times per week (subcutaneous) (e.g., Monday, Wednesday, Friday)

Cycle length

12–16 weeks

Not currently stocked by N1 Aminos. Browse what is in stock →

Overview

HMG is a purified extract from postmenopausal urine containing bioactive FSH (75IU) and LH (75IU) per vial, stimulating follicular development and ovulation induction in infertility protocols—achieving 80-90% ovulation rates and 30-40% pregnancy success in anovulatory women via multi-follicular recruitment.[conversation context] Unlike recombinant gonadotropins, HMG’s natural FSH/LH ratio mimics physiologic synergy for IVF/ICSI cycles.

Dosing (75-450IU daily) titrates to estrogen response, minimizing OHSS risk. Off-label male applications include hypogonadotropic hypogonadism reversal via spermatogenesis stimulation. For fertility preservation, PCOS ovulation induction, or hypogonadism, HMG provides dual gonadotropin restoration.[conversation context]

Studied benefits

  • Primarily used to stimulate spermatogenesis and improve sperm motility/concentration in cases of secondary infertility
  • It supports healthy testicular function and significantly increases fertility rates when combined with hCG

Reported side effects

  • Generally well-tolerated, though it may cause mild injection-site pain, fatigue, or mood changes
  • In some cases, it can lead to gynecomastia due to hormonal shifts

Protocol

Dosing Schedule (Subcutaneous)

Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.

HMG (75iu Vial)

Reconstitute with 3.0 mL bacteriostatic water (Final concentration: 25 IU/mL).

Stimulate spermatogenesis in males with hypogonadotropic hypogonadism or infertility.

Week/PhaseDose per InjectionDraw at 2.5 mg/mLLog
Weeks 1–1275 IU (0.15 mg)6 units (0.06 mL)+ Log
Weeks 13–16 (optional extension)75 IU (0.15 mg)6 units (0.06 mL)+ Log

Frequency

Three times per week (subcutaneous) (e.g., Monday, Wednesday, Friday).

Timing

Maintain consistent injection days; rotate sites with each injection.

Cycle length

12–16 weeks.

Unit calculator

Set your vial and water; the table above updates.

Open the full calculator →
Concentration

2.5 mg/mL

33 doses of 150 mcg per vial

At the starting dose (150 mcg × 3/week for a 12-week cycle) you would use about 5.4 mg, i.e. 2 × 5 mg vials. Higher phases use proportionally more.

Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.

Context

Lifestyle considerations

Follow a nutrient-dense, balanced diet rich in healthy fats and micronutrients like Vitamin D and Selenium to support the production of endogenous sex hormones and follicle stimulation. Stay physically active to maintain metabolic health and support healthy circulation to the reproductive organs. Ensure 7–9 hours of quality sleep for optimal endocrine function and to manage systemic stress levels. Periodically monitor hormonal markers (FSH and LH levels) during research protocols to ensure the dosage correctly mimics the physiological requirements for stimulating spermatogenesis or follicular development.

Evidence

Research summaries

Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF

Findings: More full-term pregnancies, better egg quality, thicker womb lining for baby attachment.

In this IVF study, HMG matched or beat lab-made FSH: 27% ongoing pregnancy rate vs 22% per cycle start. HMG grew healthier egg sacs (follicles), got more mature eggs, and built better womb prep. Fewer cancellations, similar side effects. Great for women needing strong stimulation without risks like over-swollen ovaries. Proves HMG's reliability in real clinics.

Read the study ↗

Human menopausal gonadotropins: a justifiable therapy in ovulatory women with long-standing idiopathic infertility

Findings: Pregnancies in hard cases after years trying, cheaper than IVF.

97 women ovulating but infertile long-term got HMG shots. 12% pregnant, 67% full-term babies—better than no treatment (1%) or placebos (4%). Simple, monitored cycles worked well, low multiples. Ideal first step before invasive stuff, safe with ultrasound guidance.

Read the study ↗

Highly Purified Human Menopausal Gonadotropin (HP-hMG) Versus Recombinant Follicle-Stimulating Hormone (rFSH)

Findings: Cheaper live births, fewer transfers needed, less ovary swelling.

Models from real data showed HP-HMG won on cost/results for egg-heavy responders: more pregnancies (169 vs 157), babies (161 vs 152), fewer procedures. Cut hyperstimulation risks. Even if prices shift, HMG saves money long-term for families/clinics.

Read the study ↗

Application of Human Menopausal Gonadotropins in the Treatment of Idiopathic Hypogonadotropic Hypogonadism (IHH)-Based Infertility in Females

Findings: Restarts ovulation, leads to healthy pregnancy in hormone-low women.

A young woman with IHH (no natural ovulation) used HMG after tests. It grew eggs perfectly, ovulated, and pregnancy succeeded safely. Blood/scans confirmed response. Shows HMG fixes rare gaps effectively with monitoring.

Read the study ↗
More references (4)

Identification

Chemistry

cas
9002-68-0
formula
C₆₀₉H₉₆₉N₁₆₁O₁₇₅S₇ (estimated for glycosylated protein; variations depending on glycan composition)
molecular weight
-
source
Natural; produced endogenously by anterior pituitary gonadotroph cells; now also produced via recombinant DNA technology
biosynthesis
Ribosomal origin; synthesized as precursor, proteolytically processed, then post-translationally glycosylated
type
Linear 111-amino acid protein with N-linked glycosylation

Keep exploring

Related peptides

Educational use only. The protocols shown summarise published research and community practice for informational purposes. They are not medical advice, not a prescription, and not a recommendation to use any compound. Research peptides are generally not approved for human use. Consult a licensed clinician. Full disclaimer.
Ask the advisor